Jorge O. Sanchez O.

CD markers very simplified! CD34+ = Blast CD3+ = T-cell CD19+ = B-cell CD33+ = Myeloid CD34+ = Acute leukemia (but which type?) CD34+ CD19+ = B-ALL CD34+ CD3+ = T-ALL CD34+ CD33+ = AML CD34- CD33+ = APL (promyelocyte differentiated one step above blast)”

RT 😂🌮 Hard to argue—NEOADAURA is definitely looking muy bueno so far. Exciting signal for EGFR+ early-stage NSCLC, even if we’re still waiting on long-term outcomes @dominicandoc2 @COlazagasti @mgonzalezvelMD @MomaVelez11 @IMG_Oncologists @EsmirnaPrzR @JorgeOct_ @Florez_Lab

@NarjustFlorezMD @TumorBoardTues @Latinamd @benlevylungdoc @StephenVLiu @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 #TumorBoardTuesday #LCSM Great discussion. Current approach: 👉 MRD-negative status does NOT change my rec to give adj osi in eligible stage II EGFR+ #NSCLC. MRD is predictive—but not yet validated to guide treatment de-escalation. Prospective MRD-guided trials are ongoing.

10/23 #TumorBoardTuesday @TumorBoardTues @MPishvaian Importantly, osimertinib is currently the only adjuvant therapy in resected NSCLC to demonstrate a statistically significant overall survival benefit in a biomarker-defined population. nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

🧠✨ Happening TODAY! Join us at 8 PM ET for a deep dive into early-stage #NSCLC & #NeoADAURA Excited to join @NarjustFlorezMD — don’t miss it! #TumorBoardTuesday #LungCancer @oncodaily @Florez_Lab @mgonzalezvelMD @MomaVelez11 @dominicandoc2 @Arthur_Aung @JorgeOct_

From how to read a clinical trial to... How We Read FDG PET/CT: 🩻 link.springer.com/article/10.118… Totally different topic but still very important for oncology

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming. Which one are you watching? @OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

What are plenary sessions for ASCO 2026 ? Titles are just out Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri

A MUST-READ! This is probably one of my most important papers where I try to teach how to fish rather than offer fish. How I Read a Clinical Trial Report? BG’s primer for Busy Clinicians. Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful. ascopubs.org/doi/10.1200/OP…

Beyond ATRA syndrome → We used to call it ATRA syndrome. But the biology is bigger. ATRA, ATO, IDH1/2 and FLT3 inhibitors all force leukemia to mature. And when too many cells mature at once: → cytokines surge → endothelium activates → capillary leak begins Clinical pattern: Fever + hypoxia + fluid overload ≠ infection → think DS Key principles: 🔥 Dexamethasone immediately ⚖️ Continue vs HOLD based on severity 🧠 Control the substrate  → Hydroxyurea first-line  → Gemtuzumab ozogamicin if needed Steroids treat the syndrome. Cytoreduction controls the fuel. Miss that—and you’re treating smoke, not fire. #AML #Hemetwitter

This is why we do the work! We’re hopeful that we can build on this progress and allow more patients to access these promising treatments.

The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge! Also today afternoon. #AACR26

Thanks @OncBrothers!!

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

@PoleDoctress Go for it!

He's meeting me in Amsterdam for a few days at the end of the month lol. Should I start an international situationship just for the plot?

If eos < 1,500 don’t worry about it! Redefining Hematology Referral Thresholds for Eosinophilia - Patel - European Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/ej…

Amazing to be a leukemia MD in this day & age. This is the timeline of new💊approvals in AML that I get to show our @MCG_AUG Heme/Onc fellows. The last decade has sure been exciting. What's next? #leusm #MedEd

Today one of my patients asked me, “Is this the beginning of the end?” I nodded, tears in my eyes. Sometimes a career in medicine feels like a thousand little heartbreaks. You know what’s going to unfold in front of you & it pains you, yet you choose to stay present anyway.

🧬 VEXAS Syndrome: A Medical Breakdown 🔤 What does VEXAS stand for? 🔹 V - Vacuoles (Cytoplasmic vacuoles in myeloid & erythroid precursors) 🔹 E - E1 Enzyme (Affected protein: E1 ubiquitin-activating enzyme) 🔹 X - X-linked (UBA1 gene mutation on X-chromosome) 🔹 A - Autoinflammatory (Fever, chondritis, neutrophilic dermatoses, vasculitis) 🔹 S - Somatic (Acquired mutations, not germline) 📊 Epidemiology 🔹 Male preponderance (~96% of cases), typically age >50. 🔹 Female patients often have Turner syndrome (45,X) or acquired monosomy X in bone marrow. 🩺 Diagnosis ✅ Gold Standard: Genetic testing showing somatic UBA1 mutation via NGS (most commonly affecting codon 41) 🔍 Supportive Finding: Cytoplasmic vacuoles in myeloid/erythroid precursors (suggestive but not diagnostic) 🩸 Clinical Associations 🔹 Myelodysplastic Syndrome (MDS) Connection: - Co-occurs in 18-80% of VEXAS cases (Depending on the criteria used for MDS diagnosis) - Usually presents as lower-risk MDS - Low progression rate to acute myeloid leukemia 💊 Treatment Strategies 🔥 For Autoinflammation: *Corticosteroids (first-line for symptoms) *IL-6 inhibitors, IL-1 inhibitors, & JAK inhibitors (steroid-sparing agents) 🧬 For Genetic Burden: *Hypomethylating agents (azacitidine) to reduce mutated UBA1 allelic burden *Effective even without co-existing MDS 🏥 For Severe Cases: Allogeneic stem cell transplant for carefully selected patients with: *Progressive bone marrow failure *Treatment-refractory autoimmune symptoms ❌ What Doesn't Work: *Conventional DMARDs typically ineffective for autoinflammatory symptoms Educational thread, not medical advice. Bone marrow micrograph from the ASH Image bank.

Precision oncology continues to expand in lung cancer — and HER2 is a key frontier. @lungoncdoc takes the stage to discuss “Tackling HER2 Mutations: Targeted Strategies in Lung Cancer.” @gotoPER #WLC26 #lungcancer #GotoPER #MJHLifeSciences